<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sjögren, Lovisa</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of PDE-5 Inhibition in Patients with T2DM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-25</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with obesity, insulin resistance, and T2DM have postprandial hyperglycemia and impaired postprandial microvascular response. This article reviews results from the Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes study [NCT01238224], which investigated the effect of tadalafil on postprandial hyperglycemia and circulating levels of proinflammatory markers in patients with T2DM after a mixed meal.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>